Announcements 2026
Half Year Operational Update : 15 July 2026
Change of Corporate Broker
Result of Annual General Meeting
CIZ1B Biomarker Test Approved For Clinical Use in USA
Patent Granted in USA
Notice of Annual General Meeting
Issue of Options, Salary Waivers and New Management Incentive Plan
Conversion of Convertible Loan Notes
Final Results for the year ended 31 December 2025
£250,000 Funding Facility
Progress on Commercial Launch of Biomarker Test in USA
Patent Granted in Canada : 04/02/2026